GlaxoSmithKline said Tuesday it is changing how its sales reps are compensated, and will stop making direct payments next year to doctors for speaking engagements and for attending medical conferences to promote its products.
Last year, GlaxoSmithKline agreed to pay $3 billion to settle an investigation into alleged improper marketing practices of company products.
Earlier this year, a few company executives were accused of bribery and tax fraud in China as part of an effort to boost product sales in that country.
The London-based pharmaceutical company, which has a large presence in the Philadelphia region, said Tuesday that, during 2014, it will implement a new compensation system which will apply to all GlaxoSmithKline (NYSE: GSK) sales employees worldwide who work directly with prescribing doctors. Read more about this story on PBJ.com
More NBC10.com stories:
